BiotechReality – Covering Industry, Business, and Academia
Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.
Gilead has paused dosing in its Phase 1b studies of GS-1720 and GS-4182—two promising long-acting HIV-1 therapies after identifying tolerability issues. No serious adverse events were reported, and the company is evaluating future development pathways.
The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
A SciRealityPress Associate
Contents in the website is licensed under CC BY-NC 4.0
Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio